Antibodies against cisplatin-modified DNA and cisplatin-modified (di) nucleotides

P. M. A. B. Terheggen(The Netherlands Cancer Institute), L. Den Engelse(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), E. L. M. Lempers(Leiden University), B.G.J. Floot(The Netherlands Cancer Institute), Adrian C. Begg(The Netherlands Cancer Institute)

Cancer Chemotherapy and Pharmacology

May 1, 1991

10.1007/bf00685507

Cited by 27

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

|Cell|1994|2.3k

Overcoming the blood–brain tumor barrier for effective glioblastoma treatment

|Drug Resistance Updates|2015|1k

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

|Proceedings of the National Academy of Sciences|1997|941

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

|Proceedings of the National Academy of Sciences|1997|884

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

|PubMed|2002|688